关键词

Management of dyslipidemias; simvastatin; coronary heart disease; primary prevention of cardiovascular disease; cholesterol-lowering treatment; hypertriglyceridemia; statins; stroke prevention; guidelines; clinical practice

全文

PDF

参考

[1] Catapano, A. L., Graham, I., De Backer, G., et al. (2016). 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias: The Task
Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS).
European Heart Journal, 37(39), 2999-3058.
[2] Pedersen, T. R., Kjekshus, J., et al. (1994). Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the
Scandinavian Simvastatin Survival Study (4S). The Lancet, 344(8934), 1383-1389.
[3] Shepherd, J., Cobbe, S. M., et al. (1995). Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of
Scotland Coronary Prevention Study Group. New England Journal of Medicine, 333(20), 1301-1307.
[4] Grundy, S. M., Stone, N. J., et al. (2019). 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report
of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation, 140(11),
e596-e646.
[5] Cholesterol Treatment Trialists' (CTT) Collaboration, Baigent, C., Blackwell, L., et al. (2005). Efficacy and safety of cholesterol-lowering
treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. The Lancet, 366(9493), 1267-1278.
[6] National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in
Adults (Adult Treatment Panel III). (2002). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection,
Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation, 106(25), 3143-3421.
[7] Jacobson, T. A., Ito, M. K., Maki, K. C., et al. (2015). National Lipid Association Recommendations for Patient-Centered Management of
Dyslipidemia: Part 2. Journal of Clinical Lipidology, 9(4 Suppl), S1-S122.e1.
[8] Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents, Kavey, R. E., Daniels, S.
R., et al. (2011). Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents: summary
report. Pediatrics, 128 Suppl 5, S213-S256.
[9] Berglund, L., Brunzell, J. D., et al. (2012). Evaluation and Treatment of Hypertriglyceridemia: An Endocrine Society Clinical Practice
Guideline. Journal of Clinical Endocrinology & Metabolism, 97(9), 2969-2989.
[10] Sousa, M. O., Fonseca, F. A., et al. (2016). Pleiotropic Effects of Statins: A Focus on the Management of Dyslipidemia and
Cardiovascular Risk. Current Cardiology Reviews, 12(4), 331-337.
[11] Negi, S., Shrivastava, V., et al. (2018). A Comprehensive Review on the Role of Statins in Stroke Prevention. Journal of Stroke and
Cerebrovascular Diseases, 27(12), 3635-3646.
[12] Barter, P. J., Caulfield, M., et al. (2007). HDL Cholesterol, Very Low Levels of LDL Cholesterol, and Cardiovascular Events. New
England Journal of Medicine, 356(13), 1301-1310.